Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is a monoclonal antibody approved for use in patients with relapsing multiple sclerosis (MS) as well as moderate to severe Crohn's disease. We report the first case of a patient with a history of MS, on monthly natalizumab, who developed HSV-2 meningitis. We discuss the mechanism of action of natalizumab and review what is known about the reactivation of herpes infection in association with this medication. The question of herpes simplex virus (HSV) and varicella zoster virus (VZV) prophylaxis for patients is raised.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of NeuroVirology|
|State||Published - Jun 2011|
ASJC Scopus subject areas
- Clinical Neurology
- Cellular and Molecular Neuroscience